8-K 1 wndm_8k.htm CURRENT REPORT Blueprint
 
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 19, 2017
 
Wound Management Technologies, Inc.
(Exact name of registrant as specified in its charter)
 
 Texas
 000-11808
 59-2219994
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (I.R.S. Employer Identification No.)
 
 1200 Summit Ave, Suite 414
Fort Worth, Texas
 
 76102
 (Address of principal executive offices)
 
 (zip code)
 
Registrant’s telephone number, including area code: (817) 529-2300
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[ ]             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[ ]             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ]             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ]             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
Effective as of July 19, 2017, Deborah J. Hutchinson retired as president of Wound Management Technologies, Inc. and each of its wholly owned Subsidiaries, collectively (the “Company”) in which she served in that position. Ms. Hutchinson has agreed to help the Company manage a smooth transition.
 
 
 
 
2
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Wound Management Technologies, Inc.
 
 
 
 
 
Date: July 25, 2017
By:  
/s/  J. Michael Carmena
 
 
 
 J. Michael Carmena
 
 
 
 Chief Financial Officer
 
 
 
 
 
 
3